- Home
- OFS vs ALEC Comparison
OFS vs ALEC Comparison
Compare OFS & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFS
- ALEC
- Stock Information
- Founded
- OFS 2001
- ALEC 2013
- Country
- OFS United States
- ALEC United States
- Employees
- OFS N/A
- ALEC N/A
- Industry
- OFS Finance/Investors Services
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OFS Finance
- ALEC Health Care
- Exchange
- OFS Nasdaq
- ALEC Nasdaq
- Market Cap
- OFS 110.3M
- ALEC 101.1M
- IPO Year
- OFS 2012
- ALEC 2019
- Fundamental
- Price
- OFS $8.83
- ALEC $1.14
- Analyst Decision
- OFS
- ALEC Buy
- Analyst Count
- OFS 0
- ALEC 7
- Target Price
- OFS N/A
- ALEC $4.10
- AVG Volume (30 Days)
- OFS 57.1K
- ALEC 809.4K
- Earning Date
- OFS 05-01-2025
- ALEC 05-07-2025
- Dividend Yield
- OFS 15.67%
- ALEC N/A
- EPS Growth
- OFS N/A
- ALEC N/A
- EPS
- OFS 2.12
- ALEC N/A
- Revenue
- OFS $47,964,000.00
- ALEC $100,558,000.00
- Revenue This Year
- OFS N/A
- ALEC N/A
- Revenue Next Year
- OFS N/A
- ALEC $376.51
- P/E Ratio
- OFS $4.09
- ALEC N/A
- Revenue Growth
- OFS N/A
- ALEC 3.60
- 52 Week Low
- OFS $7.75
- ALEC $0.87
- 52 Week High
- OFS $10.04
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- OFS 55.08
- ALEC 49.12
- Support Level
- OFS $8.20
- ALEC $0.90
- Resistance Level
- OFS $8.66
- ALEC $1.24
- Average True Range (ATR)
- OFS 0.42
- ALEC 0.11
- MACD
- OFS 0.03
- ALEC 0.04
- Stochastic Oscillator
- OFS 94.06
- ALEC 72.97
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.